Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Key Takeaways From ASH 2023: Emerging Trends in Hematologic Oncology

February 6, 2024
By Julie M. Vose, MD, MBA
Publication
Article
OncologyONCOLOGY Vol 38, Issue 2
Volume 38
Issue 2
Pages: 45

Julie M. Vose, MD, MBA, gave a brief overview of the 2023 American Society of Hematology Annual Meeting & Exposition, as well as what to be on the lookout for in 2024.

Julie M. Vose, MD, MBA, gave a brief overview of the 2023 American Society of Hematology Annual Meeting & Exposition, as well as what to be on the lookout for in 2024.

Julie M. Vose, MD, MBA, gave a brief overview of the 2023 American Society of Hematology Annual Meeting & Exposition, as well as what to be on the lookout for in 2024.

There have been several breakthroughs in nonmalignant hematology care recently, including the 2023 FDA approvals of Casgevy and Lyfgenia for the treatment of patients with sickle cell disease.1 During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, results from the phase 2/3 CLIMB SCD-121 trial (NCT03745287) using exagamglogene autotemcel (exa-cel) were presented, demonstrating the utility of editing ex vivo with CRISPR-Cas9 technology of the erythroid-specific enhancer region of BCL11A.2 This resulted in increased hemoglobin F production, with 96.7% of patients with severe sickle cell disease being free from vaso-occlusive events and 100% being free from hospitalization.

Additional studies were presented for patients with severe β-thalassemia who received exa-cel; more than 90% of patients achieved transfusion independence, with an improvement in quality of life.3 Another potentially major accomplishment for patients with severe hemophilia A or B was presented with the treatment of marstacimab, a novel monoclonal antibody that neutralizes tissue factor pathway inhibitor.4 This antibody then increases thrombin through the extrinsic pathway. Taken together, these therapies represent major advancements in the treatment of these nonmalignant hematologic disorders.

Several updates on outcomes of clinical trials and real-world experiences for hematologic malignancies were also presented at ASH. A late-breaking abstract of the phase 3 SYMPATICO study (NCT03112174) of ibrutinib (Imbruvica) plus venetoclax (Venclexta) vs ibrutinib plus placebo for patients with relapsed mantle cell lymphoma was presented. The results demonstrated a statistically significant improvement in progression-free survival (PFS) for the combination of ibrutinib plus venetoclax vs ibrutinib plus placebo.5

In the phase 3 Perseus trial (NCT03710603), the results from the randomized trial of daratumumab (Darzalex) plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) vs VRd alone for patients with newly diagnosed multiple myeloma who were eligible for autologous stem cell transplant were presented.6 With a median follow-up of 47.5 months, the PFS was significantly improved in the D-VRd arm at 84.3% vs 67.7% in the VRd arm.

In the plenary session, the phase 2 AGAVE-201 study (NCT04710576) of axatilimab for the treatment of chronic graft-vs-host disease was presented. Over 75% of the patients, who had disease with which prior FDA-approved therapy had failed, demonstrated a response to axatilimab, with a median failure-free survival of 17 months.7 Several of the malignant hematology studies also demonstrated the importance of minimal residual disease–negative status in multiple myeloma, non-Hodgkin lymphoma, and acute leukemias.8

With the continued progress in understanding the diagnosis, biology, and treatments for patients with malignant and nonmalignant hematologic disorders, the future remains bright for
our patients.

REFERENCES

  1. FDA approves first gene therapies to treat patients with sickle cell disease. News release. FDA. December 8, 2023. Accessed January 24, 2024. https://shorturl.at/axyJS
  2. Frangoul, H, Locatelli F, Sharma A, et al. Exagamglogene autotemcel for severe sickle cell disease.Blood. 2023;142(suppl 1):1052. doi:10.1182/blood-2023-190139
  3. Locatelli, F, Lang P, Corbacioglu S, et al. Exagamglogene autotemcel for transfusion-dependent β-thalassemia. Blood. 2023;142(suppl 1):1053. doi:10.1182/blood-2023-190534
  4. Matino D, Acharya S, Palladino A, et al. Efficacy and safety of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results of the phase 3 Basis trial. Blood. 2023;142(suppl 1):285. doi:10.1182/blood-2023-181263
  5. Wang M, Jurczak W, Trněný M, et al. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 Sympatico study. Blood. 2023;142(suppl 2):LBA-2. doi:10.1182/blood-2023-191921
  6. Sonneveld P, Dimopoulos M, Boccadoro M, et al. Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus Vrd alone in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation (ASCT): primary results of the Perseus trial. Blood. 2023;142(suppl 2):LBA-1. doi:10.1182/blood-2023-191911
  7. Wolff D, Cutler C, Lee SJ, et al. Safety and efficacy of axatilimab at 3 different doses in patients with chronic graft-versus-host disease (AGAVE-201). Blood. 2023;142(suppl 1):1. doi:10.1182/blood-2023-186963
  8. Roschewski M, Lindenberg L, Mena E, et al. End-of-treatment response assessment after frontline therapy for aggressive B-cell lymphoma: landmark comparison of singular PET/CT versus ultrasensitive circulating tumor DNA. Blood. 2023;142(suppl 1):192. doi:10.1182/blood-2023-180007
Download Issue PDF
Articles in this issue

Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma
Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma
Pediatric-Inspired Asparaginase Regimens for Patients With Acute Lymphocytic Leukemia
Pediatric-Inspired Asparaginase Regimens for Patients With Acute Lymphocytic Leukemia
Building on Recent Advances and Facing New Challenges in MCL
Building on Recent Advances and Facing New Challenges in MCL
MCL Treatment Advances and Future Directions
MCL Treatment Advances and Future Directions
Recent Advances in the Understanding of MCL Biology
Recent Advances in the Understanding of MCL Biology
Consortium Effort Drives Progress in Mantle Cell Lymphoma Research
Consortium Effort Drives Progress in Mantle Cell Lymphoma Research
Twenty Years of Advancing  Discoveries and Treatment of  Mantle Cell Lymphoma
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
Key Takeaways From ASH 2023: Emerging Trends in Hematologic Oncology
Key Takeaways From ASH 2023: Emerging Trends in Hematologic Oncology
Recent Videos
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Related Content
Advertisement

We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

American Society for Transplantation and Cellular Therapy
September 3rd 2025
Article

Researchers from the BMT CTN reported that posttransplant cyclophosphamide-based GVHD prophylaxis significantly improves outcomes for adults aged 70 years and older undergoing allo-HCT.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Exa-cel Exhibits Meaningful HRQoL Benefit in Severe Sickle Cell Disease

Roman Fabbricatore
August 31st 2025
Article

The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.


Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Ariana Pelosci
August 25th 2025
Article

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.

Related Content
Advertisement

We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

American Society for Transplantation and Cellular Therapy
September 3rd 2025
Article

Researchers from the BMT CTN reported that posttransplant cyclophosphamide-based GVHD prophylaxis significantly improves outcomes for adults aged 70 years and older undergoing allo-HCT.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Exa-cel Exhibits Meaningful HRQoL Benefit in Severe Sickle Cell Disease

Roman Fabbricatore
August 31st 2025
Article

The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.


Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Ariana Pelosci
August 25th 2025
Article

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.